Literature DB >> 17307974

Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Mette D Jacobsen1, Julie A Whyte, Frank C Odds.   

Abstract

Candida dubliniensis isolates tested for susceptibility to anidulafungin, caspofungin, and micafungin commonly showed artifactual regrowth and/or trailing effects with MIC tests done under conditions involving a high initial yeast concentration. The artifacts were less common with Candida albicans and seldom seen for either species under Clinical and Laboratory Standards Institute method M27-A test conditions.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17307974      PMCID： PMC1855534          DOI： 10.1128/AAC.01525-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Antifungal agents: mechanisms of action.

Authors:  Frank C Odds; Alistair J P Brown; Neil A R Gow
Journal:  Trends Microbiol       Date:  2003-06       Impact factor: 17.079

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors:  J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Authors:  C M Douglas; J A D'Ippolito; G J Shei; M Meinz; J Onishi; J A Marrinan; W Li; G K Abruzzo; A Flattery; K Bartizal; A Mitchell; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Studies of the paradoxical effect of caspofungin at high drug concentrations.

Authors:  David A Stevens; Theodore C White; David S Perlin; Claude P Selitrennikoff
Journal:  Diagn Microbiol Infect Dis       Date:  2005-03       Impact factor: 2.803

6.  Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; E Mellado; J L Rodriguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2005-06       Impact factor: 8.067

7.  Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Authors:  M B Kurtz; G Abruzzo; A Flattery; K Bartizal; J A Marrinan; W Li; J Milligan; K Nollstadt; C M Douglas
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

8.  Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Authors:  Beth A Arthington-Skaggs; Wendy Lee-Yang; Meral A Ciblak; Joao P Frade; Mary E Brandt; Rana A Hajjeh; Lee H Harrison; Andre N Sofair; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Different consequences of ACE2 and SWI5 gene disruptions for virulence of pathogenic and nonpathogenic yeasts.

Authors:  Donna M MacCallum; Helen Findon; Claire C Kenny; Geraldine Butler; Ken Haynes; Frank C Odds
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441
View more
  11 in total

1.  Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes.

Authors:  Mohamed Khlif; Hervé Bogreau; Annie Michel-Nguyen; Ali Ayadi; Stéphane Ranque
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

Review 2.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.

Authors:  Keunsook K Lee; Donna M Maccallum; Mette D Jacobsen; Louise A Walker; Frank C Odds; Neil A R Gow; Carol A Munro
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates.

Authors:  Ana Espinel-Ingroff; E Canton; J Peman; E Martín-Mazuelo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

5.  Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.

Authors:  Marçal Mariné; F Javier Pastor; Ismail H Sahand; José Pontón; Guillermo Quindós; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

Review 6.  Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

Authors:  Sarah A Cross; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.

Authors:  M Fleischhacker; C Radecke; B Schulz; M Ruhnke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-04       Impact factor: 3.267

8.  Candida albicans and Candida dubliniensis Show Different Trailing Effect Patterns When Exposed to Echinocandins and Azoles.

Authors:  Rania Ayadi; Emilie Sitterlé; Christophe d'Enfert; Eric Dannaoui; Marie-Elisabeth Bougnoux
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

9.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495

Review 10.  Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.

Authors:  Sofia Costa-de-Oliveira; Acácio G Rodrigues
Journal:  Microorganisms       Date:  2020-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.